Tim Opler’s latest biopharma market update covers industry sentiment, M&A activity, capital markets & more. The biotech market has come roaring back in the last ten months. The XBI has nearly doubled.
Biopharma Market Update
Stifel
Tim Opler
Research
64 Pages
Key Takeaways
Optimistic Outlook: Opler remain quite positive on direction and still think the XBI can cross 150 this year.
Impressive earnings growth With the exception of Novo, which has been slammed on a negative growth forecast, larger pharmas have seen strong earnings growth. Last week saw Amgen, J&J, Lilly, Novartis and Roche hit all-time highs.
Low Retail Participation: The two big heated markets in biotech of the last thirty years coincided with massive retail entry into biotech associated with these two events. This is missing from the market at the moment.